Fluocinolone + Neomycin


Generic Medicine Info
Indications and Dosage
Topical/Cutaneous
Corticosteroid-responsive dermatoses with secondary infection
Adult: Available preparation:
Each cream or ointment contains fluocinolone 0.025% and neomycin base 0.35%

Apply thinly onto affected area bid-tid up to 7 days.
Contraindications
Hypersensitivity to neomycin. Perforated eardrum. Infections caused by bacteria, fungi, or viruses and in rosacea, acne, perioral dermatitis and napkin eruptions.
Special Precautions
Patient with hypersensitivity to gentamicin, kanamycin, paromomycin, streptomycin; minor or major skin damages. Application on intertriginous or flexor areas; use of occlusive dressings. Children. Pregnancy and lactation. Not intended for ophthalmic use. Avoid prolonged use.
Adverse Reactions
Significant: Local irritation, hypersensitivity reactions, steroid withdrawal. Rarely, atrophy of the skin and the subcutaneous tissues due to prolonged application; ototoxicity, nephrotoxicity, hypothalamic-pituitary-adrenal axis suppression, Cushing’s syndrome, hyperglycaemia, glucosuria.
Infections and infestations: Folliculitis. Rarely, secondary or opportunistic infections.
Skin and subcutaneous tissue disorders: Pruritus, dryness, burning sensation, dermatitis, new or worsening acne, hypopigmentation, maceration, striae, miliaria, hypertrichosis.
Monitoring Parameters
Monitor signs of bacterial or fungal infection.
Drug Interactions
May increase risk of adverse reactions associated to systemic absorption with other corticosteroids.
Action
Description: Fluocinolone is a topical corticosteroid that has immunosuppressant, anti-inflammatory, antipruritic and vasoconstrictive properties. It induces phospholipase A2 inhibitory proteins (lipocortin) and sequentially inhibits the release of arachidonic acid, thereby depressing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. histamine, kinins).
Neomycin, an aminoglycoside antibacterial, is bactericidal against a variety of gram-positive and gram-negative organisms. It inhibits bacterial protein synthesis by irreversibly binding to 30S ribosomal ribonucleic acid subunits.
Pharmacokinetics:
Absorption: Fluocinolone: Absorbed from intact skin; increased if inflamed.
Neomycin: Poorly absorbed from intact skin; increased if inflamed.
Metabolism: Fluocinolone: Metabolised in the liver.
Excretion: Fluocinolone: Mainly via urine; bile.
Neomycin: Via urine (30-50% as unchanged drug).
Chemical Structure

Chemical Structure Image
Fluocinolone

Source: National Center for Biotechnology Information. PubChem Database. Fluocinolone, CID=91488, https://pubchem.ncbi.nlm.nih.gov/compound/Fluocinolone (accessed on Jan. 21, 2020)


Chemical Structure Image
Neomycin

Source: National Center for Biotechnology Information. PubChem Database. Neomycin, CID=8378, https://pubchem.ncbi.nlm.nih.gov/compound/Neomycin (accessed on Jan. 21, 2020)

Storage
Store below 25°C.
MIMS Class
Topical Anti-Infectives with Corticosteroids
References
Anon. Fluocinolone (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/04/2018.

Anon. Neomycin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/04/2018.

Buckingham R (ed). Fluocinolone Acetonide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/04/2018.

Buckingham R (ed). Neomycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/04/2018.

Joint Formulary Committee. Fluocinolone Acetonide with Neomycin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/04/2018.

Neo-Synalar (Medimetriks Pharmaceuticals). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/04/2018.

Synalar N Cream (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 12/04/2018.

Synalar N Ointment (Reig Jofre UK Limited). MHRA. https://products.mhra.gov.uk/. Accessed 12/04/2018.

Disclaimer: This information is independently developed by MIMS based on Fluocinolone + Neomycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in